| Sakeena Jamaluddin Payne, MD | |
|
924 Colonial Ave Ste E, York, PA 17403-3450 | |
| (717) 843-9089 | |
| Not Available |
| Full Name | Sakeena Jamaluddin Payne |
|---|---|
| Gender | Female |
| Speciality | Otolaryngology |
| Experience | 12 Years |
| Location | 924 Colonial Ave Ste E, York, Pennsylvania |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1598023962 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | MD463966 (Pennsylvania) | Secondary |
| 207Y00000X | Otolaryngology | S0056 (Texas) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| The Ent And Allergy Centers Of Texas, Pllc | 4385709054 | 46 |
News Archive
BioElectronics Corp. (PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free anti-inflammatory devices, today announces its schedule for filing with the U.S. government's Food and Drug Administration for 510(K) pre-marketing clearance for its ActiPatch® Therapy and RecoveryRx™ products. In these applications BioElectronics will seek over-the-counter clearance of its ActiPatch Therapy product for indications for the treatment of heel and foot pain, and for pain relief relative to general musculoskeletal complaints.
Men are more prone to competitive risk taking and violent behavior, so what happens when the number of men is greater than the number of women in a population?
President Barack Obama's re-election is viewed as a "reprieve" for the health law but this development raises questions and issues about some of the implementation challenges that the overhaul will now face.
Silicon Biosystems, S.p.A., a provider of specialized molecular and cell biology technology, today announced that it has formed a U.S. subsidiary operation, Silicon Biosystems, Inc., to be headquartered in San Diego, California. The newly formed business will focus on commercial operations and the development of the North American research and clinical diagnostics markets for the company's DEPArray™ technology platform.
Centhaquine, a new medication to treat patients who have severe blood or fluid loss, significantly improved outcomes and reduced death rate when added to standard of care, compared to standard care alone, according to preliminary research to be presented at the American Heart Association's Resuscitation Science Symposium 2020.
› Verified 3 days ago
| Entity Name | The Ent & Allergy Centers Of Texas, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144470873 PECOS PAC ID: 4385709054 Enrollment ID: O20090212000145 |
News Archive
BioElectronics Corp. (PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free anti-inflammatory devices, today announces its schedule for filing with the U.S. government's Food and Drug Administration for 510(K) pre-marketing clearance for its ActiPatch® Therapy and RecoveryRx™ products. In these applications BioElectronics will seek over-the-counter clearance of its ActiPatch Therapy product for indications for the treatment of heel and foot pain, and for pain relief relative to general musculoskeletal complaints.
Men are more prone to competitive risk taking and violent behavior, so what happens when the number of men is greater than the number of women in a population?
President Barack Obama's re-election is viewed as a "reprieve" for the health law but this development raises questions and issues about some of the implementation challenges that the overhaul will now face.
Silicon Biosystems, S.p.A., a provider of specialized molecular and cell biology technology, today announced that it has formed a U.S. subsidiary operation, Silicon Biosystems, Inc., to be headquartered in San Diego, California. The newly formed business will focus on commercial operations and the development of the North American research and clinical diagnostics markets for the company's DEPArray™ technology platform.
Centhaquine, a new medication to treat patients who have severe blood or fluid loss, significantly improved outcomes and reduced death rate when added to standard of care, compared to standard care alone, according to preliminary research to be presented at the American Heart Association's Resuscitation Science Symposium 2020.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Sakeena Jamaluddin Payne, MD 5220 W University Dr Ste 150, Mckinney, TX 75071-7418 Ph: (972) 984-1050 | Sakeena Jamaluddin Payne, MD 924 Colonial Ave Ste E, York, PA 17403-3450 Ph: (717) 843-9089 |
News Archive
BioElectronics Corp. (PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free anti-inflammatory devices, today announces its schedule for filing with the U.S. government's Food and Drug Administration for 510(K) pre-marketing clearance for its ActiPatch® Therapy and RecoveryRx™ products. In these applications BioElectronics will seek over-the-counter clearance of its ActiPatch Therapy product for indications for the treatment of heel and foot pain, and for pain relief relative to general musculoskeletal complaints.
Men are more prone to competitive risk taking and violent behavior, so what happens when the number of men is greater than the number of women in a population?
President Barack Obama's re-election is viewed as a "reprieve" for the health law but this development raises questions and issues about some of the implementation challenges that the overhaul will now face.
Silicon Biosystems, S.p.A., a provider of specialized molecular and cell biology technology, today announced that it has formed a U.S. subsidiary operation, Silicon Biosystems, Inc., to be headquartered in San Diego, California. The newly formed business will focus on commercial operations and the development of the North American research and clinical diagnostics markets for the company's DEPArray™ technology platform.
Centhaquine, a new medication to treat patients who have severe blood or fluid loss, significantly improved outcomes and reduced death rate when added to standard of care, compared to standard care alone, according to preliminary research to be presented at the American Heart Association's Resuscitation Science Symposium 2020.
› Verified 3 days ago
Dr. Carol Linda St George, D.O. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1776 S Queen St, York, PA 17403 Phone: 717-845-6261 Fax: 717-852-0630 | |
Ms. Renuka Kyatham Reddy, MD Otolaryngology Medicare: Medicare Enrolled Practice Location: 924 Colonial Ave Ste E, York, PA 17403 Phone: 717-843-9089 Fax: 717-843-6075 | |
Dr. Brent Emmerich Yoder, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 924 Colonial Ave Ste E, York, PA 17403 Phone: 717-843-9089 Fax: 717-843-6075 | |
Dr. Andrew R Shorb, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 924 Colonial Ave Ste E, York, PA 17403 Phone: 717-843-9089 Fax: 717-843-6075 | |
Dr. Brian K Flowers, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 924 Colonial Ave, Bldg E, York, PA 17403 Phone: 717-843-9089 Fax: 717-843-6075 | |
Genevieve Ann Andrews, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 924 Colonial Ave Ste E, York, PA 17403 Phone: 717-843-9089 Fax: 717-843-6075 |